PCV50 COST-EFFECTIVENESS ANALYSIS COMPARING DABIGATRAN AND ADJUSTED-DOSE WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION
May 1, 2011, 00:00
10.1016/j.jval.2011.02.237
https://www.valueinhealthjournal.com/article/S1098-3015(11)00376-7/fulltext
Title :
PCV50 COST-EFFECTIVENESS ANALYSIS COMPARING DABIGATRAN AND ADJUSTED-DOSE WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)00376-7&doi=10.1016/j.jval.2011.02.237
First page :
A41
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
788